AbbVie in line for hefty payout after Takeda breached supply contract on Lupron

Thanks to a contract manufacturing deal with Takeda gone awry, AbbVie appears to be in line to receive hundreds of millions of dollars in damages.

The Delaware Court of Chancery sided with AbbVie Tuesday, granting the drugmaker nearly all of the $480.6 million it was seeking in damages from Takeda over a botched supply agreement for Lupron, according to Bloomberg Law.